Ton Logtenberg

This inventor holds 59 USPTO granted patents and 33 published patent applications, plus 12 CIPO patents and 20 EPO patents, primarily in Bispecific Antibodies (CPC class C07K). Top assignees: Merus N.v., Merus B.v., Crucell Holland B.v.. Active years: 2001-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ton Logtenberg. Retrieved from https://idiyas.com/inventor/ton-logtenberg

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 59 (Patent Applications = 33)

% Patents Active = 86.4

CIPO Patents = 12 (Patent Applications = 18)

EPO Patents = 20 (Patent Applications = 40)

Average Co-Inventor Count = 3.3

ph-index = 17

Forward Citations = 1,156(Granted Patents)

Forward Citations (Not Self Cited) = 689(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Werkhoven, NL (2010)
Driebergen-Rijensburg, NL (2018)
Utrecht, NL (2001 - 2024)
Driebergen, NL (2006 - 2024)

Company Filing History:

Fundacio Institut De Recerca Biomedica

patent

5. 1 out of 92

Institucio Catalana De Recerca I Estudis Avancats

patents

6. 1 out of 1

Merus Biopharmaceuticals B.v.

patent

7. 1 out of 1

Merus Biopharmaceuticals, B.v.i.o.

patent

8. 1 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 2001-2026

Loading Chart...

Areas of Expertise:

Bispecific Antibodies

Binding Molecules

Cancer Treatment

EGFR

ErbB-2

ErbB-3

T Cell Engagers

NRG1 Fusion Gene

PD-1

TIM-3

CD137

cMET

59 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12723095 - METHODS OF TREATING CANCER USING BINDING MOLECULES THAT BIND CD137 AND PD-L1 (2026-09-01),

2. 12668638 - ANTIBODIES THAT BIND EGFR AND CMET (2026-06-30),

3. 12577306 - BISPECIFIC ANTI PD1-ANTI TIM3 ANTIBODIES (2026-03-17),

4. 12291798 - Generation of binding molecules (2025-05-06),

5. 12247078 - ERBB-2 and ERBB-3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene (2025-03-11),

6. 12139548 - Antibody that binds ErbB-2 and ErbB-3 (2024-11-12),

7. 12123043 - Methods and means for the production of Ig-like molecules (2024-10-22),

8. 12060418 - Bispecific IgG antibodies as T cell engagers (2024-08-13),

9. 11952424 - Multivalent antibody (2024-04-09),

10. 11939394 - Binding molecules that inhibit cancer growth (2024-03-26),

11. 11926859 - Methods and means for the production of Ig-like molecules (2024-03-12),

12. 11925174 - Antibody producing non-human animals (2024-03-12),

13. 11820825 - Methods of treating a subject having an EGFR-positive and/or ErbB-3-positive tumor (2023-11-21),

14. 11785924 - Antibody producing non-human animals (2023-10-17),

15. 11780925 - ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene (2023-10-10),

Title: Inventor Ton Logtenberg

Introduction: Ton Logtenberg is a renowned inventor based in Utrecht, Netherlands, known for his groundbreaking contributions to the field of biotechnology.

Latest Patents: Logtenberg holds several patents in the biotechnology sector, focusing on innovative solutions for healthcare and pharmaceutical industries.

Career Highlights: With a career spanning over two decades, Ton Logtenberg has been instrumental in developing cutting-edge technologies that have revolutionized the medical field. His work has led to significant advancements in drug delivery systems and personalized medicine.

Collaborations: Throughout his career, Logtenberg has collaborated with leading research institutions, universities, and pharmaceutical companies to bring his inventions to life. His collaborative efforts have resulted in the successful commercialization of several groundbreaking technologies.

Conclusion: Ton Logtenberg's passion for innovation and his dedication to improving healthcare have established him as a prominent figure in the world of biotechnology. His contributions continue to have a lasting impact on the industry, shaping the future of medicine.

Profile summary based on public USPTO records.